Company Analysis

Estrella Immunopharma, Inc. (ESLA)

Nasdaq: ESLA · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2021
Grade4.0
◀ Past 2.7● Present 3.4▶ Future 5.4
7 est.

Who runs Estrella Immunopharma, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Pussinen Cynthia
Chief Executive Officer. First filing Nov 2026, latest Nov 4, 2026, 0 filings in all.
Officers reporting now
3
of 4 people with a filing in the last fifteen months
Directors reporting now
1
15 people on the record since 2021
Officerssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Pussinen CynthiaChief Executive OfficerNov 2026Nov 4, 2026none
Liu ChengCEOOct 2023Aug 26, 2026none
Xu JiandongChief Financial OfficerOct 2023Aug 25, 2026none
Directorssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
Jia DengyaodirectorOct 2025Oct 1, 2025none
Earlier names on the record15, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ESLA · research, not advice